Highlights from the 7th Cachexia Conference: Muscle wasting pathophysiological detection and novel treatment strategies

Nicole Ebner, Lisa Steinbeck, Wolfram Doehner, Stefan D. Anker, Stephan von Haehling

Research output: Contribution to journalArticlepeer-review

Abstract

This article highlights preclinical and clinical studies in the field of wasting disorders that were presented at the 7th Cachexia Conference held in Kobe, Japan, in December 2013. This year, the main topics were the development of new methods and new biomarkers in the field of cachexia and wasting disorders with particular focus on inflammatory pathways, growth differentiation factor-15, myostatin, the ubiquitin proteasome-dependent pathway, valosin and the regulation of ubiquitin-specific protease 19 that is involved in the differentiation of myogenin and myosin heavy chain. This article presents highlights from the development of drugs that have shown potential in the treatment of wasting disorders, particularly the ghrelin receptor agonist anamorelin, the myostatin antagonist REGN1033, the selective androgen receptor modulators enobosarm and TEI-E0001, and the anabolic catabolic transforming agent espindolol. In addition, novel data on the prevalence and detection methods of muscle wasting/sarcopenia are presented, including the D3-creatine dilution method and several new biomarkers.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalJournal of Cachexia, Sarcopenia and Muscle
Volume5
Issue number1
DOIs
Publication statusPublished - 2014

Keywords

  • Cachexia
  • Muscle wasting
  • Sarcopenia
  • Therapy

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Highlights from the 7th Cachexia Conference: Muscle wasting pathophysiological detection and novel treatment strategies'. Together they form a unique fingerprint.

Cite this